A strategy to target and block this ATM/TRIM37/NEMO axis has been developed via a cell-penetrating HIV-1 transactivator of transcription (TAT)-conjugated TRIM37/TBM (TAT-TRIM37/TBM) peptide which can compete for the formation of the complex including TRIM37, resulting in a hypersensitivity of cancer cells to genotoxic drugs [83]. This evidence concerns the gene TRIM37 and cancer.